Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tod Bushman

Podiatrist, Foot & Ankle Surgery Mt Juliet, TN Doctor of Podiatric Medicine

NPI 1417952581 CMS profile 1200652

660 S Mount Juliet Rd Ste 230, Mt Juliet, TN 37122

Open in the dashboard

General payments

$4,805

290 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$355,800

6 holdings reported · through program year 2025

Through program year 2025, Tod Bushman of Mt Juliet, TN is reported in the CMS Open Payments database as having received $4,805 across 290 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $355,800 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $637 27
2024 General $634 29
2023 General $482 22
2022 General $677 36
2021 General $745 52
2020 General $954 75
2019 General $676 49
2024 Ownership $80,100 1
2023 Ownership $80,100 1
2022 Ownership $59,500 1
2021 Ownership $46,100 1
2020 Ownership $45,000 1
2019 Ownership $45,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tod Bushman
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Tod Bushman were reported at $637. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Tod Bushman Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $676 $389 $118–$1,406 $163
2020 $954 $191 $62–$691 $114
2021 $745 $329 $104–$1,341 $132
2022 $677 $419 $125–$1,611 $149
2023 $482 $377 $128–$1,164 $160
2024 $634 $394 $134–$1,168 $164
2025 $637 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,768 161 payments
  2. Stryker Corporation $242 7 payments
  3. Paratek Pharmaceuticals, Inc. $210 12 payments
  4. Organogenesis Inc. $200 4 payments
  5. LifeNet Health $177 12 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $163 10 payments
  7. PolyNovo North America LLC $154 4 payments
  8. Aroa Biosurgery Incorporated $146 6 payments
  9. Kerecis Limited $132 3 payments
  10. KCI USA, Inc $105 1 payment
  11. Other $1,508 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,805 290 payments
Products named General payments · program years 2019–2025
  1. Stravix Other Advanced Wound Management $726 68 payments
  2. GRAFIX PL Other Advanced Wound Management $325 26 payments
  3. GRAFIX PL Other Advanced Wound Management $220 18 payments
  4. NUZYRA $210 12 payments
  5. STRAVIX Extremities & Limb Restoration $200 26 payments
  6. TheraGenesis Wound Matrix $177 12 payments
  7. JUBLIA $163 10 payments
  8. GRAFIX Other Advanced Wound Management $157 5 payments
  9. NOVOSORB BTM $154 4 payments
  10. GRAFIX Other Advanced Wound Management $154 13 payments
  11. Other $2,746 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,084

Median for Podiatry: 160

Drug cost

$36,373

Median for Podiatry: $2,368

Branded share of claims

16.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 27 $19,915
Ciclopirox Generic 139 $3,088
Pregabalin Generic 121 $2,768
Ketoconazole Generic 62 $1,799
Gabapentin Generic 155 $1,665
Doxycycline Hyclate Generic 135 $1,228
Linezolid Generic 14 $1,187
Clobetasol Propionate Generic 18 $1,148
Mupirocin Generic 93 $721
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 52 $714

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$131,496

Of which drugs: $16

Medicare patients

482

Average age 76

Services billed

2,071

264 women, 218 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 49%
Chronic kidney disease 43%
Ischemic heart disease 35%
Depression 27%
Heart failure 23%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 16 170 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $70
$70 — —
Qutenza
  • Averitas Pharma Inc. $62
$62 — —
KRYSTEXXA
  • Amgen Inc. $20
$20 — —
DALVANCE
  • AbbVie, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record